Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.
The trial was based on results from early phase I/II trials that showed that elotuzumab and lenalidomide are synergistic when given together, said Lonial. There was also a better overall response rate and longer progression-free survival with the addition of elotuzumab.
Lonial says more than 300 patients were randomized to each arm, and roughly one-third of patients had high-risk disease at the time of initial presentation.
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma. This was a randomized phase III trial that evaluated the benefit of elotuzumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone without elotuzumab.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy
March 20th 2024During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.
Read More